Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 40 Neoplasms, Plasma Cell 5 Neoplasms 5 Recurrence 4 Renal Insufficiency 3 Paraproteinemias 3 Hematologic Diseases 3 Smoldering Multiple Myeloma 2 Neoplasms by Histologic Type 2 Hematologic Neoplasms 2 Blood Protein Disorders 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasm, Residual 1 Natural Killer/T-cell Lymphoma 1 Monoclonal Gammopathy of Undetermined Significance 1 Lymphoproliferative Disorders 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Leukemia, Plasma Cell 1 Immunoproliferative Disorders 1 Immunoglobulin Light-chain Amyloidosis 1 Hodgkin Disease 1 Cryoglobulinemia, Familial Mixed 1

Interventions

isatuximab 1 cemiplimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Natural Killer/T-cell Lymphoma × isatuximab × Clear all

NCT04763616 2026-04-27

ICING

Samsung Medical Center

Phase 2 Completed

Natural Killer/T-cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡